Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Mar 22, 2024 7:35am
35 Views
Post# 35946569

RE:RE:Legalization coming soon

RE:RE:Legalization coming soonWe have the cash to ride it out, provided break even in near and we don't venture off into a stupid M&A exercise.

GMP also is not something that countries gift and there is a LONG process that gives LABS prime-mover benefit, along with other approvals (see recent Brazil).  Naturally the longer it takes to monetize those things the less of an advantage they are but we still do have runway IMO.

That said, LABS leadership needs to make step change gains in topline in the immediate term.  There is nothing stopping them at this point.  We need to be much higher in topline revs by end of calendar year or we can conclude they haven't been focusing on the right things.
<< Previous
Bullboard Posts
Next >>